ABT ABBOTT LABORATORIES Insider Trading

Director John G Stratton purchases 2,000 shares of Abbott at $86.82; stock down 36.4% from 52-week high

John G Stratton acquired 2,000 shares at $86.82, expanding his position to 23,319 shares from 21,319 shares. The transaction occurs with Abbott's stock trading at $88.41, down 36.4% from its 52-week high of $139.06. The company reported net income of $1,077,000,000.00 on revenue of $11,164,000,000.00 in the latest quarter, with annual revenue growth of +5.7%. The context shows a material pullback from peak valuations, though fundamentals remain intact with a P/E of 24.56 and market cap of $153,993,636,847.89.

Director Daniel J. Starks buys 10,000 Abbott shares, signaling conviction amid recent stock decline.

Daniel J. Starks, a board member at Abbott Laboratories, purchased 10,000 shares in late April as the stock traded well below its recent highs and had declined meaningfully over the prior quarter. This director-level buy occurs against a backdrop of Abbott's solid fundamentals—the company is profitable with steady revenue growth and operates with reasonable valuation metrics. Starks's purchase, while modest in proportional terms relative to his overall holdings, represents active conviction in the company's direction at a time when the stock has faced near-term pressure. The timing suggests a board member sees value in the current dislocation and is willing to deploy personal capital despite the recent pullback, which often carries more weight than routine trading activity. This directional signal warrants monitoring to see if other board members or executives follow suit, which would reinforce the conviction thesis.

Abbott Labs C-suite insider buys over 11K shares amid stock pullback; signals conviction in healthcare giant

A senior Abbott insider made a substantial open-market purchase of over 11,000 shares while the stock has retreated meaningfully from its highs and declined over the past three months, suggesting conviction at depressed valuations. Abbott remains a profitable, revenue-growing healthcare company with solid fundamentals and a reasonable valuation, making this accumulation noteworthy rather than a desperate catch-as-catch-can bid. The insider's significant capital commitment—over $1 million deployed across two transactions on the same day—indicates confidence that the current weakness is a buying opportunity, not a red flag. The timing of this purchase into a temporary pullback, combined with the company's stable operational performance, suggests the insider views current prices as attractive relative to intrinsic value. This type of meaningful insider accumulation during a dip often precedes investor recognition of value.

Director Starks purchases 10,000 shares at blended avg $108.73, bringing stake to 6.74M shares as ABT down 12.8% in 30 days.

Director Daniel J. Starks executed 2 separate purchases totaling 10,000 shares for $1,087,331.40 on 2026-02-04 at prices of $109.14 and $108.33. His post-transaction holdings reach 6.74M shares (+0.1% net change). The current price of $110.83 sits -21.0% from the 52-week high and -12.8% below the 30-day prior close, establishing recent downward momentum. Starks' prior trading at ABT shows 5 historical transactions (5 sales between May–October 2023), of which 2 of 5 were well-timed at the 90-day horizon; his cross-ticker track record across 6 sells shows a 50% well-timed rate at 90 days, suggesting moderate success with sell timing. The purchase size and dollar volume ($1.1M) are material and deliberate, executed as two distinct tranches on the same day, and the timing occurs against a backdrop of recent price decline from peak levels. Investors should note the magnitude of this acquisition relative to his existing position and monitor whether this signals forward-looking conviction or responds to perceived value at current depressed levels relative to 52-week history.

Ford (CEO) buys 18.8K ABT shares at $107.13; holdings rise to 216.2K amid 22.4% decline from 52-week high

Robert B. Ford, Abbott's Chairman and CEO, purchased 18,800 shares at $107.13 on 2026-01-23, increasing his stake to 216,203 shares. The purchase occurs while the stock is -22.4% from its 52-week high and has declined 12.9% over the prior 30 days and 14.1% over 90 days. Historically, Ford's prior open-market trades across all tickers show a 90-day well-timed rate of 66.67% on 3 prior sells; his same-ticker history at ABT spans 3 prior transactions (all sales), with 2 of 3 exhibiting negative 90-day returns. The timing context—a material price decline from recent peaks—and the magnitude (+9.5% increase to his ABT holdings) merit investor attention, though the fundamental context shows reasonable metrics: Abbott's P/E of 13.53 and recent quarterly net income of $1,644,000,000 provide a baseline for evaluation.

ABT CFO Philip Boudreau sold 5,550 shares at $134.55 on 2025-08-08, reducing holdings by 9.8% to 51,003 shares.

Philip Boudreau, EVP and CFO of Abbott Laboratories, sold 5,550 shares at $134.55 for total proceeds of $746,758.05. The transaction reduced his post-transaction holdings to 51,003 shares, representing a 9.8% reduction from his prior position of 56,553 shares. At the time of the sale, the stock was trading near its 52-week high of $140.22 and currently trades at $131.36, down 6.3% from the peak. Abbott's fundamentals remain solid with quarterly revenue of $11,142,000,000.00, net income of $1,779,000,000.00, and year-over-year revenue growth of 4.6%, yielding a P/E ratio of 16.36 on a market cap of $228,626,696,079.04. The sale occurred at prices proximate to the 52-week high range and merits standard insider activity review.

EVP Lisa D Earnhardt sold 91,367 shares of ABT for $12,227,296.94 across 2 separate sales; post-transaction holdings 71.9K shares (-56.0% reduction)

Lisa D Earnhardt, EVP and Group President of Abbott Laboratories, executed 2 separate open-market sales totaling 91,367 shares for $12,227,296.94 between March 6–7, 2025, at a blended average price of $133.83. This sale reduced her holdings from 163,295 shares to 71,928 shares, representing a -56.0% reduction in position size. Her prior sales history at Abbott shows a 90-day return of +2.2% (poorly timed), meaning her previous sale was followed by stock appreciation rather than decline. The current price of $137.14 is -2.2% from the 52-week high and up +18.6% over the 90-day period, indicating the stock has performed strongly in the recent period. Given the substantial reduction in holding concentration and the stock's strong recent momentum, investors should monitor whether this large sale signals a material change in senior management's conviction or is routine portfolio management by a highly-compensated executive.

Abbott CEO Robert Ford sells 285.4K shares (56.5% of holdings) for $37.4M at $131.17

Ford Robert B, Chairman and CEO, conducted a substantial sale of 285,388 shares on 2025-02-05 at $131.17, reducing his holdings from 505,447 to 220,059 shares and realizing $37,435,200.12. This represents a -56.5% reduction in his post-transaction position. The sale occurred near the 52-week high ($132.06), with the transaction price only -2.3% below the annual peak. His cross-ticker track record shows 2 prior sells with a 90-day well-timed rate of 100.00%, indicating his past sales preceded stock declines; at Abbott specifically, both prior sales in September 2024 were also well-timed at the 90-day mark, with the stock falling -1.6% and -2.4% after those trades. The current stock price of $129.07 is -1.6% below the transaction price, and ABT has gained +13.0% over 30 days and +10.7% over 90 days, extending its strength into 2025. The company faces headwinds with annual revenue growth declining -8.1% year-over-year, a P/E of 38.88, and most recent quarterly net income of $1,646,000,000 against revenue of $10,635,000,000. A CEO's sale of over half his holdings near the year-high, coupled with his consistent pattern of well-timed exits at this ticker, warrants investor attention to whether this signals conviction about near-term valuation or reflects portfolio rebalancing at an elevated price point.

EVP Allen Hubert sold 189,788 shares of ABT for $24,342,303.62 across 2 transactions, reducing holdings by 50.7%

ALLEN HUBERT L executed two separate sales totaling 189,788 shares (189.8K shares) for $24,342,303.62 ($24.3M) at a blended average price of $128.26, reducing his ABT holdings from 374,594 shares to 184,806 shares. His prior three sales at Abbott (all on 2024-10-21) demonstrated a 100% timing pattern at the 90-day mark, with negative returns following each sale. The stock currently trades at $127.93, near its 52-week high of $129.43 (-1.2%), while Abbott's fundamentals show annual revenue decline of -8.1% despite a substantial market cap of $221,888,855,399.09 ($221.9B) and P/E of 38.53. This substantial reduction in executive holdings—eliminating more than half of his position—occurs in a context of both strong near-term price momentum (+13.1% over 30 days) and concerning longer-term revenue headwinds at the company.

EVP Salvadori sold 23,771 ABT shares at $128.50 (Jan 30), reducing stake by 15.9% to 125,697 shares

Salvadori Daniel Gesua Sive, EVP at Abbott Laboratories, executed a sale of 23,771 shares at $128.50 for a total value of $3,054,573.50, reducing his holdings from 149,468 shares to 125,697 shares. The sale occurred near the upper bound of the 52-week range ($100.07–$129.43), with the stock currently trading at $127.93 (30-day and 90-day momentum positive at +13.1% and +7.9%, respectively). The company faces macroeconomic headwinds, with annual revenue declining 8.1% year-over-year despite a substantial market capitalization of $221.9B. Without disclosure of whether this transaction followed a scheduled trading plan, the sale pattern itself—a 15.9% reduction in holdings at a near-peak valuation—warrants monitoring as part of broader insider activity at the company.